Preclinical and clinical strategies for development of telomerase and telomere inhibitors

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1063-1074

  Sharma, S ^a,b   Raymond, E ^a   Soda, H ^a   Sun, D ^a   Hilsenbeck, S G ^b   Sharma, A ^b   Izbicka, E ^a   Windle, B ^a   Von Hoff, D D ^a  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cancer; Chemotherapy; Telomerase; Telomeres

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOTOXIC AGENT; ENZYME INHIBITOR; MITOXANTRONE; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; TAMOXIFEN; TELOMERASE;

BLOOD TOXICITY; BREAST CANCER; CANCER; CLINICAL TRIAL; DRUG RESISTANCE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; IMMUNOTOXICITY; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN TOXICITY; TELOMERE;

ANIMALS; BREAST NEOPLASMS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DNA REPLICATION; DNA, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASMS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TELOMERASE; TELOMERE;

EID: 0030671246     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008206420505     Document Type: Review

References (116)

1. McClintock B. The fusion of broken ends of chromosomes following nuclear fusion. Proc Natl Acad Sci USA 1942; 28: 458-63.
2. Zakian VA. Telomeres: Beginning to understand the end. Science 1995; 270: 1601-7.
3. Lustig AJ. Involvement of the silencer and UAS binding protein RAP1 in regulation of telomere length. Science 1990; 250: 549-53.
4. Chikashige Y, Ding DQ, Funabiki H et al. Telomere-led premeiotic chromosome movement in fission yeast. Science 1994; 264: 270-3.
5. Watson JD. Origin of concatameric T4 DNA. Nature 1972; 239: 197-201.
6. Olvonikov AM. A theory of marginotomy. J Theor Biol 1971; 41: 181-90.
7. West MD. The cellular and molecular biology of skin aging. Arch Dermatol 1994; 130: 87-95.
8. Wright WE, Shay JW. Time, telomeres and tumors: Is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5: 293-7.
9. Harley CB, Vaziri H, Counter CM, Allsopp RC. The telomere hypothesis of cellular aging. Exper Gerontol 1992; 27: 375-82.
10. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-36.
11. Hastie ND, Dempster M, Dunlop MG et al. Telomere reduction in human colorectal carcinoma and aging. Nature 1990; 346: 866-8.
12. Shay JW, Van Der Haegen BA, Ying Y, Wright WE. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 1993; 209: 45-52.
13. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989; 337: 331-7.
14. Blasco MA, Funk W, Villeponteau B, Greider CW. Functional characterization and developmental regulation of mouse telomerase RNA. Science 1995; 269: 1267-70.
15. Melek M, Davis BT, Shippen DE. Oligonucleotides complementary to Oxutricha nova telomerase RNA delineate the template domain and uncover a novel mode of primer utilization. Mol Cell Biol 1994; 14; 7827-38.
16. Singer MS, Gottschling DE. Template RNA component of Saacharomyces cerevisiae telomerase. Science 1994; 266: 404-9.
17. Feng J, Funk WD, Wang SS et al. The RNA component of human telomerase. Science 1995; 269: 1236-41.
18. Pathak S, Wang Z, Dhaliwal MK, Sacks PC. Telomeric association: Another characteristic of cancer chromosomes? Cytogenet Cell Genet 1988; 47: 227-9.
19. Holzmann K, Blin N, Welter C et al. Telomeric associations and loss of telomeric DNA repeats in renal tumors. Genes Chrom Cancer 1993; 6: 178-81.
20. Saltman D, Morgan R, Cleary ML, de Lange T. Telomeric structure in cells with chromosome end associations. Chromosoma 1993; 102: 121-8.
21. Bacchetti S. Telomere maintenance in tumor cells. Cancer Surveys 1996; 28: 197-216.
22. Henderson S, Allsopp R, Spector D et al. In situ analysis of changes in telomere size during replicative aging and cell transformation. J Cell Biol 1996; 134: 1-12.
23. Anonymous. A complete set of human telomeric probes and their clinical application. National Institutes of Health and Institute of Molecular Medicine Collaboration. Nat Genet 1996; 14: 86-9.
24. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer Science 1994; 266: 2011-5.
25. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92: 9082-6.
26. Counter CM, Leber B, Harley CB, Bacchetti S. Telomere length and telomerase activity in hematological malignancies. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A3308.
27. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995; 92: 4818-22.
28. Tatematsu K, Nakayama J, Danbara M et al. A novel quantitative 'stretch PCR assay' that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene 1996; 13: 2265-74.
29. Brousset P, Saati TA, Chaouche N et al. Telomerase activity in reactive and neoplastic lymphoid tissues: Infrequent detection of activity in Hodgkin's disease. Blood 1997; 89: 26-31.
30. Piatyszek PA, Kim NW, Weinrich SL et al. Detection of telomerase activity in human cells and tumors by a telomere repeat amplification protocol. Methods Cell Sci 1995; 17: 1-15.
31. Sun D, Chen S-F, Von Hoff D. A sensitive and rapid assay method of human telomerase using dynabeads. In Lobbezoo MW (ed): 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam: Colophon ed./Dordrecht: Kluwer Academic Publishers 1996.
32. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 1996; 16: 2932-9.
33. Lundblad V, Wright WE. Telomeres and telomerase: A simple picture becomes complex (Meeting Review). Cell 1996; 87: 369-75.
34. Xu D, Gruber A, Peterson C, Pisa P. Supression of telomerase activity in HL-60 cells after treatment with differentiating agents. Leukemia 1996; 10: 1354-7.
35. Bestilny LJ, Brown CB, Miura Y et al. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res 1996; 56: 3796-802.
36. Albanell J, Han W, Mellado B et al. Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant tumor cell lines. Cancer Res 1996; 56: 1503-8.
37. Sharma HW, Sokoloski JA, Perez JR et al. Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci USA 1995; 92: 12343-6.
38. Sharma S, Raymond E, Soda H et al. Telomerase activity during cell cycle in a lymphoma cell line. Proc Annu Meet Am Assoc Cancer Res 1997; 38: A3383.
39. Allsopp RC, Harley CB. Evidence for a critical telomere length in senescent human fibroblasts. Exp Cell Res 1995; 219: 130-6.
40. Counter CM, Avilion AA, LeFeuvre CE et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-9.
41. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. Experimental elongation of telomeres extends the lifespan of immortal X normal cell hybrids. EMBOJ 1996; 15: 1734-41.
42. Ohyashiki JH, Ohyashiki K, Fujimura T et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994; 54: 3557-60.
43. Ohmura H, Tahara H, Suzuki M et al. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3. Jpn J Cancer Res 1995; 86: 899-904.
44. Yegorov YE, Chernov DN, Akimov SS et al. Reverse transcriptase inhibitors supress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett 1996; 389: 115-8.
45. Raymond E, Sun D, Chen S-F et al. Agents that target telomerase and telomeres. Curr Opin Biotech 1996; 7: 583-91.
46. Hamilton SE, Corey DR. Telomerase: Anti-cancer target or just a fascinating enzyme? Chemistry & Biol 1996; 3: 863-7.
47. Norton JC, Piatyszek MA, Wright WE et al. Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotech 1996; 14: 615-9.
48. Joshi SS, Palen BN, Mata JE, Iversen PL. Growth inhibitory effects of telomere mimic-oligonucleotides on human leukemia/ lymphoma cells in vitro. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A2449.
49. Iversen PL, Pirruccello SJ, Mata JE, Joshi SS. Antisense oligonucleotides which demonstrate tumor specific action also inhibit telomerase in vitro. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A2455.
50. Kanazawa Y, Ohkawa K, Ueda K et al. Hammerhead ribozymemediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biophys Biochem Res Commun 1996; 225: 570-6.
51. Strahl C, Blackburn EH. The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res 1994; 22: 893-900.
52. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996; 16: 53-65.
53. Salazar M, Thompson BD, Kerwin SM, Hurley LH. Thermally induced DNA-RNA hybrid to G-Quadruplex transitions: Possible implications for telomere synthesis by telomerase. Biochemistry 1996; 35: 16110-5.
54. Fletcher TM, Salazar M, Chen S-F. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates. Biochemistry 1996; 35: 15611-7.
55. Thompson B, Salazar M, Sun D et al. Telomerase inhibition by G-quartet interactive compounds. In Lobbezoo MW (ed): 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam: Colophon ed./Dordrecht: Kluwer Academic Publishers 1996.
56. Sharma S, Raymond E, Soda H et al. A model for telomerase inhibition in lymphomas. In Dillman RO (ed): Fourth International Conference on Biologic Response Modifiers. San Antonio, TX: Inter-American Society of Chemotherapy 1997.
57. Xiao X, Bardot V, Wientjes MG, Au JL-S. Cell death is accompanied by an increase in telomerase activity. Proc Am Assoc Cancer Res 1996; 37: A3844.
58. Ohyashiki K, Ohyashiki JH, Iwama H et al. Clinical implications in telomerase activity in acute leukemia. Proc Am Soc Hematol 1996; 371a: A1464.
59. Chadeneau C, Siegel P, Harley CB et al. Telomerase activity in normal and malignant murine tissues. Oncogene 1995; 11: 893-8.
60. Prowse KR, Avilion AA, Greider CW. Identification of a non-processive telomerase activity from mouse cells. Proc Natl Acad Sci USA 1993; 90: 1493-7.
61. Starling JA, Maule J, Hastie ND, Allshire RC. Extensive telomere repeat arrays in mouse are hpervariable. Nucleic Acids Res 1990; 18: 6881-8.
62. Kipling D, Cooke HJ. Hypervariable ultra-long telomeres in mice. Nature 1990; 347: 400-2.
63. Kubota T. Metastatic models of human cancer xenografted in the nude mouse: Importance of orthoptic transplantation. J Cell Biochem 1994; 56: 4-8.
64. Clarke R. Huamn breast cancer line xenografts as models of breast cancer: The immunobiologies of recipient mice and the characteristics of several tumorigenic lines. Breast Cancer Res Treat 1996; 39: 69-86.
65. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metast Rev 1986; 5: 29-49.
66. Gilewski T, Norton L. Cytokinetics and breast cancer chemotherapy. In Harris JR, Morrow M, Lippman ME, Hellman S (eds): Diseases of the Breast. Philadelphia: Lippincott-Raven 1996.
67. Teicher BA, Holden SA, Ara G. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 1994; 57: 920-5.
68. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: Biological rationale and challenges for their evaluation. Ann Oncol 1996; 7: 441-4.
69. Hohaus S, Cavallo S, Bellacosa A et al. Telomerase activity in human laryngeal squamous cell carcinomas. Clin Cancer Res 1996; 2: 1895-900.
70. Marshall E. Haematopoietic stem cell inhibition: Potential for dose intensification. Eur J Cancer 1995; 10: 1586-91.
71. Lajtha LG, Pozzi LV, Schofield R, Fox M. Kinetics of properties of haematopoietic stem cells. Cell Tissue Kinet 1969; 2: 39-49.
72. Shay JW, Werbin H, Wright WE. Telomeres and telomerases in human leukemias. Leukemia 1996; 10: 1255-61.
73. Hiyama K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 155: 3711-5.
74. Potten CS. Cell cycle in cell hierarchies. Int J Radiat Biol 1986; 2: 273-8.
75. Bocci V. Central nervous system toxicity of interferons and other cytokines. J Biol Regulat Homeost Agents 1988; 3: 107-18.
76. Butler MG. Sciadini M, Hedghes LK, S.S. S. Chromosome telomere integrity of human solid neoplasms. Cancer Genet Cytogenet 1996; 86: 50-3.
77. Schmitt H, Blin N, Zankl H, Scherthan H. Telomere length variation in normal and malignant human tissues. Genes Chromosom Cancer 1994; 11: 171-7.
78. Rogalla P, Rohen C, Bonk U, Bullerdiek J. Telomeric repeat fragment lengths are not correlatd to histological grading in 85 breast cancers. Cancer Lett 1996; 106: 155-61.
79. Mehle C, Piatyszek MA, Ljungberg B et al. Telomerase activity in human renal cell carcinoma. Oncogene 1996; 13: 161-6.
80. Gupta J, Han L-P, Wang P et al. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst 1996; 88: 1152-7.
81. Bryan TM, Englezou A, Gupta J et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-8.
82. Murnane JP, Sabatier L, Marder BA, Morgan WF. Telomere dynamics in an immortal human cell line. EMBO J 1994; 13: 4953-62.
83. Rogan EM, Bryan TM, Hukku B et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995; 15: 4745-53.
84. Windle B, Maine IP, Wajima M, Chen SF. Nucleotide specificity and inhibition of telomerase, and cellular resistance to telomerase inhibition. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A3310.
85. Kyo S, Kanaya T, Ishikawa H et al. Telomerase activity in gynecologiic cancers. Clin Cancer Res 1996; 2: 2023-8.
86. Taylor RS, Ramirez RD, Ogoshi M et al. Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 1996; 106: 759-65.
87. Sommerfeld HJ, Meeker AK, Piatyszek MA et al. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218-22.
88. Lin Y, Miyamamoto H, Fujinami K et al. Telomerase activity in human bladder cancer. Clin Cancer Res 1996; 2: 929-32.
89. Mutirangura A, Supiyaphun P, Trirekapan S et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3530-3.
90. Hiyama K, Hiyama E, Ishioka S et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995; 87: 895-901.
91. Norrback KF, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B cells and non-Hodgkin's lymphomas. Blood 1996; 88: 222-9.
92. Nouso K, Urabe Y, Higashi T et al. Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma. Cancer 1996; 78: 232-6.
93. Counter CM, Gupta J, Harley CB et al. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315-20.
94. Zhang W, Piatyszek MA, Kobayashi T et al. Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation inducing agents. Clin Cancer Res 1996; 2: 799-803.
95. Hiyama E, Yokoyama T, Tatsumoto N et al. Telomerase activity in Gastric Cancer. Cancer Res 1995; 55: 3258-62.
96. Tahara H, Kuniyasu H, Yokozaki H et al. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1995; 1: 1245.
97. Chadeneau C, Hay K, Hirte HW et al. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995; 55: 2533-6.
98. Li Z-H, Salovaara R, Aaltonen LA, Shibata D. Telomerase activity is commonly detected in hereditary nonpolyposis colorectal cancers. Am J Pathol 1996; 148: 1075-9.
99. Hiyama E, Gollahon L, Kataoka T et al. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996; 88: 116-22.
100. Bednarek AK, Sahin A, Brenner AJ et al. Analysis of telomerase activity in breast cancer: Positive detection at the in situ breast carcinoma stage. Clin Cancer Res 1997; 3: 11-6.
101. Hiyama E, Kodama T, Shinbara K et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997; 57: 326-31.
102. Hiyama E, Hiyama K, Yokoyama T et al. Correlating telomerase activity levels with human neuroblastoma outcomes [see comments]. Nature Med 1995; 1: 249-55.
103. Langford LA, Piatyszek MA, Xu R et al. Telomerase activity in human brain tumours. Lancet 1995; 346: 1267-8.
104. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma [see comments]. Proc Natl Acad Sci USA 1994; 91: 2900-4.
105. Adamson DJ, King DJ, Haites NE. Significant telomere shortening in childhood leukemia. Cancer Genet Cytogenet 1992; 61: 204-6.
106. Hiyama E, Hiyama K, Yokoyama T et al. Length of telomeric repeats in neuroblastoma: Correlation with prognosis and other biologic characteristics. Jpn J Cancer Res 1992; 83: 159-64.
107. Mehle C, Ljungberg B, Roos G. Telomere shortening in renal cell carcinoma. Cancer Res 1994; 54: 236-41.
108. Odagiri E, Kanada N, Jibiki K et al. Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer 1994; 73: 2978-84.
109. Smith JK, Yeh G. Telomere reduction in endometrial adenocarcinoma. American J Obstet Gynecol 1992; 167: 1883-7.
110. Ohashi K, Tsutsumi M, Nakajima Yet al. Telomere changes in human hepatocellular carcinomas and hepatitis virus infected noncancerous livers. Cancer 1996; 77: 1747-51.
111. Salazar M, Thompson B, Kerwin SM, Hurley L. Unwinding of telomeric hybrids is facilitated by G-quartet formation. In Lobbezoo MW (ed): 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam: Colophon ed./ Dordrecht: Kluwer Academic Publishers 1996.
112. Chen SF, Maine IP, Windle B. Effect of 3′-azidothymidine triphosphate (AZTTP) and 3′-azidothymidine (AZT) on telomerase activity and telomere function. Proc Annu Meet Am Assoc Cancer Res 1995; 36: A3302.
113. Weng N, Levine BL, June CH, Hodes RJ. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 1996; 183: 2471-9.
114. Igrashi H, Sakaguchi N. Telomerase activity is induced by the stimulation to antigen receptor in human peripheral lymphocytes. Biochem Biophys Res Commun 1996; 219: 649-55.
115. Chiu C-P, Dragowska W, Kim NW et al. Differential expression of telomerase activity in hematoopoietic progenitors from adult human bone marrow. Stem Cells 1996; 14: 239-48.
116. Yasumoto S, Kunimura C, Kikuchi K et al. Telomerase activity in normal human epithelial cells. Oncogene 1996; 13: 433-9.